Research Shows Link Between Patient Recruitment Methods and Retention
Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits.
Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits. The primary outcome for the meta-analysis measure was retention rates of subjects recruited comparing the two methods of engagement, online versus site databases. A secondary outcome was retention rates across all study visits to determine divergence patterns between the two groups.
The firm noted in a press release that higher retention levels of subjects actively engaged in seeking out a clinical trial compared to those who were passively engaged via the physician or study staff may be related to different motivations between the groups of patients. This may be due to the company's online process in which patients seeking the study online must also undergo a comprehensive vetting procedure. The company says additional research is necessary to further understand the drivers of these differences.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
